A Prescription Drug User Fee Act target date of June 23, 2025 has been set for the application. The sBLA is supported by data from the randomized, open-label phase 3 CheckMate 8HW trial ...
The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) as a first-line treatment for adults with unresectable or ...
Please provide your email address to receive an email when new articles are posted on . First-line treatment with nivolumab-ipilimumab improved PFS and response compared with monotherapy for certain ...
Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer: Results From the Randomized ...
Opdivo Qvantig (nivolumab/hyaluronidase-nvhy) is a prescription drug used to treat certain types of cancer. Opdivo Qvantig comes as a liquid that’s injected under your skin. Opdivo Qvantig is used in ...
The GCO-001-NIPINEC (ClinicalTrials.gov identifier: NCT03591731) trial was a noncomparative, open-label, phase II trial. The main inclusion criteria were age ≥18 years, performance status (PS) ≤2, ...
HCC has a high mortality rate and a rising incidence in the US, imposing substantial healthcare costs and financial hardships on patients. Although the use of immune checkpoint inhibitors has improved ...
Based on the Phase 3 CheckMate-9DW trial, Opdivo plus Yervoy demonstrated a statistically significant overall survival benefit compared to investigator’s choice of lenvatinib or sorafenib 1 In the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results